EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Stimulator of interferon genes (STING)‐activating nanomedicines: Translating innate immune modulation into effective therapy for triple‐negative breast cancer

Harshita Singhai, Taha Alqahtani, Humood Al Shmrany, Garima Gupta, Umesh Kumar Patil, Amirhossein Sahebkar, Prashant Kesharwani

Clinical and Translational Medicine · 2026

DOI: 10.1002/ctm2.70580 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Harshita Singhai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, India. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunity, Innate, Nanomedicine, Membrane Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prince sattam bin Abdulaziz University, Deanship of Scientific Research at King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC), marked by profound immunosuppressive complexity, poses a critical challenge in therapy due to the absence of hormone receptors in its phenotype, making it unavailable for conventional therapies. The stimulator of interferon genes (STING) pathway is emerging as critical pathway translating the immunogenic ‘cold’ TNBC tumour into ‘hot’ one, thereby improving the responsiveness to immune checkpoint blockade (ICB). However, the clinical translation is still hindered by insufficient cytosolic delivery, rapid systemic degradation and tumour microenvironment‐induced metabolic inactivation. This review outlines the recent advances in STING‐mediated nanoparticle delivery with special emphasis on biomimetic, Trojan horse logic gate, manganese‐based and redox‐responsive stimuli delivery systems. Mechanistically, it integrates immune activation by ferroptosis, cuproptosis and mitochondrial DNA disruption. They synergise the amplification of type 1 interferon with dendritic cell maturation, potentiating antitumour immunogenesis. Notably, the combination with ICBs will further amplify the therapeutic potential of nanoparticles. Convergence of immunology and targeted therapies with nanoparticles opens new array for TNBC treatment. The review visualizes the clinical translation of mind maps into clinical reality, activating the innate immunity. Highlights STING activation converts immunologically cold TNBC into ICB‐responsive hot tumors. Nanoparticles overcome poor delivery, degradation, and TME‐driven STING inactivation. Biomimetic and stimuli‐responsive systems enhance type I IFN and DC maturation. Synergy with ICBs boosts innate immunity and antitumor immunogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsImmunity, InnateNanomedicineMembrane ProteinsHumansFemaleNanoparticlesSTING Protein

Stichwörter der Autor:innen

cuproptosisferroptosisnanoparticle drug deliverystimulator of interferon genes (STING) pathwaytriple‐negative breast cancer

Substanzen

Membrane ProteinsSTING1 protein, humanSTING Protein

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, India.
  • Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
  • Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
  • Graphic Era Hill University, Dehradun, India.
  • School of Allied Medical Sciences, Lovely Professional University, Phagwara, Punjab, India.
  • Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Förderung

  • Prince sattam bin Abdulaziz University
  • Deanship of Scientific Research at King Khalid University

Zitieren

APA

Singhai, H., Alqahtani, T., Shmrany, H. A., Gupta, G., Patil, U. K., Sahebkar, A., & Kesharwani, P. (2026). Stimulator of interferon genes (STING)‐activating nanomedicines: Translating innate immune modulation into effective therapy for triple‐negative breast cancer. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70580

Vancouver

Singhai H, Alqahtani T, Shmrany HA, Gupta G, Patil UK, Sahebkar A, et al. Stimulator of interferon genes (STING)‐activating nanomedicines: Translating innate immune modulation into effective therapy for triple‐negative breast cancer. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70580

BibTeX
@article{Singhai2026,
  author = {Singhai, Harshita and Alqahtani, Taha and Shmrany, Humood Al and Gupta, Garima and Patil, Umesh Kumar and Sahebkar, Amirhossein and Kesharwani, Prashant},
  title = {Stimulator of interferon genes (STING)‐activating nanomedicines: Translating innate immune modulation into effective therapy for triple‐negative breast cancer},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  doi = {10.1002/ctm2.70580}
}
Kostenlos starten →